STOCKHOLM, SWEDEN--(Marketwired - April 05, 2013) -
Swedish Orphan Biovitrum AB (Sobi) today published its Annual Report for
themed "Building value for patients, partners and shareholders", on the
company's website, www.sobi.com.
The report encompasses the company's approach to keeping the patient
from diagnosis and treatment, to on-going disease management and long-term
outcomes - at the centre of how it prioritises its capabilities and
By creating and maintaining a dialogue with key stakeholders (patients
organizations, physicians, governments and payers), Sobi seeks to ensure
treatments are delivered in a sustainable way. Sobi refers to this approach
Patient and Customer Centric commercialisation.
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is
focused on inflammation and genetic diseases, with three late stage
development projects within haemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies.
a pioneer in biotechnology with world-class capabilities in protein
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9
(EUR 215 M) and about 480 employees. The share (STO: SOBI) is listed on
Stockholm. More information is available at www.sobi.com
Sobi press release April 5, 2013 in pdf version:
This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE